Health TrialsbyHealthPanel

Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia

ConditionsHypertensionDyslipidemia
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age19+
SponsorJW Pharmaceutical

About this trial

A Multi-center, Randomized, Double-blind, Parallel, Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients with Hypertension and Dyslipidemia

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients with hypertension and dyslipidemia

Disqualifiers

The subject not meet the specified msBP and LDL-C level

Trial design

Design model

Parallel

Treatments tested in this trial

  • JW0104+C2402

    Drug

    For 8 weeks(PO (Per Oral), QD)

  • JW0104+C2403

    Drug

    For 8 weeks(PO, QD)

  • C2402

    Drug

    For 8 weeks(PO, QD)

Treatment groups

162 Participants
are divided into 3 treatment groups
Group A: JW0104+C2402Experimental treatment 1 intervention
Group B: JW0104+C2403Active comparator 1 intervention
Group C: C2402Active comparator 1 intervention

Trial outcomes

Primary outcomes

1

Change from baseline in msSBP (Systolic Blood Pressure)

Check msSBP

Time frame
week 8
2

Percent change from baseline in LDL-C (Low-Density Lipoprotein Cholesterol)

Check LDL-C

Time frame
week 8

Secondary outcomes

1

change from baseline in msSBP

Check msSBP

Time frame
week 4
2

Change and percent change from baseline in LDL-C

Check LDL-C

Time frame
week 4

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

JW Pharmaceutical

Lead sponsor

Source ClinicalTrials.gov
Apply now